Alpha Sense BI
AUGUST 30, 2023
AI has become more prevalent in every part of asset management, from opportunity identification to due diligence to invest men t decision-making to perfor man ce analysis to ongoing portfolio management and more.
Alpha Sense BI
APRIL 29, 2024
Traditional due diligence for start-up investors has historically been riddled with inefficiencies—tying up resources to sort through countless documents and copious amounts of data, and manually crafting market comparisons and performance. There is no doubt that generative AI has emerged as a powerful tool in the investment space.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alpha Sense BI
MAY 28, 2024
The top three trending sectors—information technology, healthcare/biotech, and business and financial services— ushered in funding rounds over $100 million since the beginning of the year. While VC deals on the whole are down and hovering near historic lows, there is still notable activity—even some megadeals.
Alpha Sense BI
APRIL 19, 2024
Quantum Computing is Generating Investor Buzz Like spatial computing, quantum computing is a relatively new term gaining traction with investors, venture capitalists, as well as biotech and healthcare startups, demonstrating a broad range of potential use cases —including financial modeling, weather forecasting, genome sequencing, drug discovery, cryptography, (..)
Alpha Sense BI
APRIL 12, 2024
For a healthcare engineer in the biotech engineering space, I’m gonna be really technical and get down to the nitty gritty behind the actual chemistry. You’re actually talking to the technologists, like the person building the code, the person selling the code, so you create different sets of questions depending on who the person is.” ”For
Alpha Sense BI
MAY 5, 2023
Three years later, despite macroeconomic uncertainties, investors remain attracted to this space, particularly the more innovative and tech-influenced sub-sectors like biotech and MedTech. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.
Engage3
MAY 19, 2022
He has a wealth of cross-industry experience in accelerating companies’ growth and raising capital, having spent more than fifteen years in SaaS companies as CFO and COO in industries as varied as manufacturing and biotech. He holds B.A. degrees in Neuroscience and Behavior, Genetics, and Economics from Columbia University.
Expert insights. Personalized for you.
98 
Let's personalize your content